| Literature DB >> 26169748 |
M Seitz1.
Abstract
The diagnosis of polymyalgia rheumatica (PMR) is based on the typical clinical symptoms and elevated inflammatory markers in blood; however, both are unspecific and the differential diagnosis of the disease still represents a challenge for clinicians. The new consensus classification criteria of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established in 2012 have a high sensitivity (92.6 %) and specificity (91.2 %) and therefore contribute to improved diagnostics. Glucocorticoids are still the standard treatment with methotrexate and as an alternative and possibly anti-interleukin (anti-IL) 6 therapy in the future.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26169748 DOI: 10.1007/s00393-014-1548-z
Source DB: PubMed Journal: Z Rheumatol ISSN: 0340-1855 Impact factor: 1.372